Chronic Bronchitis Market: By Treatment (Pharmacological, Nonpharmacological, and Others), By Drug Class (Bronchodilators, Glucocorticoids, Antibiotics, Phosphodiesterase-4 Inhibitors, and Others), By Route of Administration (Oral, Parenteral, Inhalational, and Others), By End Users (Hospitals, Specialty Clinics, and Others) and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Chronic Bronchitis Market was valued at USD 5.8 billion in 2022 and is poised to grow at a CAGR of 5.4% over 2023-2029. Chronic Bronchitis is defined as a productive cough, one that produces sputum, which lasts for three months or more per year for at least two years, and the most common cause is tobacco smoking, including other factors such as air pollution and genetics. According to the Centers for Disease Control and Prevention, 9.3 million people were diagnosed with chronic bronchitis in the USA, in 2018. The increasing prevalence of COPD and growing chronic bronchitis market demand for combination therapy will act as the chronic bronchitis market growth drivers. However, the high cost of treatment and the lack of awareness of the disease might cause hindrance in the growth of the market. The rising prevalence of smoking and advancements in clinical research and innovations are opportunities for the expansion of the market.

Chronic Bronchitis Market Key Developments:
  • In Feb 2022, AstraZeneca and Glenmark Pharmaceuticals Ltd. entered into an exclusive licensing agreement for Budesonide inhalation suspension in Colombia.
  • In Feb 2022, Sunovion’s Brovana was approved by the US FDA for treating bronchoconstriction in chronic obstructive pulmonary disease patients.

Chronic Bronchitis Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific
Chronic Bronchitis Market Dynamics

An increasing number of smokers, and the rising prevalence of lung disorders such as bronchitis, asthma, and COPD, are the major factors driving the growth of the chronic bronchitis market. Moreover, government-led initiatives to raise awareness of the treatment of lung disorders, have resulted in progress for combination medicines and small cell therapy. Thus, the increased awareness, research, and development for chronic diseases will lead to the growth of the market within the forecast period.

Key Features of the Reports

  • The chronic bronchitis market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Chronic Bronchitis Market Segmentation

By Treatment
  • Pharmacological
  • Nonpharmacological
  • Others
By Drug Class
  • Bronchodilators
  • Glucocorticoids
  • Antibiotics
  • Phosphodiesterase-4 Inhibitors
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Inhalational
  • Others
By End User
  • Hospitals
  • Specialty Clinics
  • Others

Frequently Asked Questions

The Chronic Bronchitis market was valued at USD 5.8 million in 2022 and is expected to grow at a 5.4% CAGR over the forecast period 2023 – 2029.

The rising prevalence of smoking and advancements in clinical research and innovations are the key opportunities for the Chronic Bronchitis market.

The increasing prevalence of COPD and growing demand for combination therapy are the growth drivers in the Chronic Bronchitis market.

Bayer AG, Boehringer Ingelheim International, AstraZeneca, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceutical PLC, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnsons & Johnsons Private, limited, and GlaxoSmithKline Plc. are a few companies operating in the Chronic Bronchitis market.

  • Bayer AG
  • Boehringer Ingelheim International
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Hikma Pharmaceutical PLC
  • Amneal Pharmaceuticals LLC.
  • Aurobindo Pharma
  • Johnsons & Johnsons Private limited
  • GlaxoSmithKline Plc.